Amicus Therapeutics Welcomes Simon Harford as Maestro of Finance

A Symphony of Progress: Amicus Therapeutics Welcomes Financial Maestro Simon Harford

In a dynamic crescendo that reverberated across the biotech landscape, Amicus Therapeutics, Inc. (Nasdaq: FOLD) announced today, against the backdrop of Philadelphia’s innovation pulse on August 21, 2023, that Simon Harford has taken the helm as the Chief Financial Officer. The spotlight now shines on Simon, a virtuoso of financial leadership, as he steps into the limelight of this patient-dedicated global biotechnology virtuoso.

Simon’s journey is a harmonious composition of significant financial roles in two global pharmaceutical powerhouses, seamlessly interwoven with his recent performance as a public company CFO in the biotechnology realm. As the baton is passed, Daphne Quimi takes her final bow, retiring from the stage but leaving an indelible mark on the financial symphony that has been Amicus Therapeutics.

In a harmonious duet of gratitude and anticipation, Bradley Campbell, the President and Chief Executive Officer of Amicus Therapeutics, resonates, “With the cadence of Daphne’s retirement, we extend our gratitude for the notes of strength she infused into our company. Her legacy reverberates through our journey towards becoming a leading biotechnology entity.”

The crescendo of anticipation builds as Bradley continues, “Our new CFO, Simon Harford, brings his own melody of financial prowess to the table. His expertise will guide us as we march towards the harmonious chorus of profitability, where each note signifies a step closer to delivering innovative therapies to those fighting rare diseases.”

As the curtain draws on her chapter, Daphne Quimi reflects, “The score of Amicus’ growth over the past 15 years has been one of resounding triumph. The stage is set for Simon and me to perform a harmonious duet, supporting the global operations that resonate with the rare disease community.”

Simon himself steps into the spotlight with his own resonant chords of enthusiasm, stating, “Amicus is a symphony of potential and promise. The orchestra of leadership here is unparalleled, and I am excited to contribute my own melodies to the mix. With each note, I intend to elevate the trajectory that Amicus is on, leveraging my decades of experience to amplify our commercial presence.”

Simon’s virtuosity is well-established, with his musical journey weaving through the pharmaceutical and healthcare industry both in the U.S. and internationally. His rhythm has guided him through roles such as Chief Financial Officer at Boston-based biotech Albireo Pharma Inc., and his influence reverberated through the halls of PAREXEL International Corporation. His expertise symphonically resonates, having orchestrated financial movements at GlaxoSmithKline plc and Eli Lilly and Company.

This chapter of Amicus Therapeutics, scored with the rhythm of growth and innovation, marches forward under Simon Harford’s baton. The symphony of rare disease solutions continues to play on, with each note echoing a promise to patients and the future of biotechnology.

About Amicus Therapeutics

In the spotlight of Nasdaq’s grand stage, the captivating performance of Amicus Therapeutics (Nasdaq: FOLD) unfolds. With a global canvas and a heart dedicated to patients, this biotechnology virtuoso takes center stage, orchestrating a symphony of discovery, development, and delivery of exceptional medicines for those whose battles are against rare diseases.

With a spotlight that never dims, Amicus Therapeutics conducts a mesmerizing performance, propelling forward a pipeline adorned with gems of innovation – each a masterpiece in the making, a beacon of hope for those in need.

Forward Looking Statement

“This press release invites you into a realm of possibility, embracing the spirit of innovation and anticipation. Among the words that dance across these lines—’expect,’ ‘believe,’ ‘encourage,’ and ‘potential’—you’ll find the heartbeat of forward-looking statements. Within these words lies the essence of our aspirations, carefully woven into the fabric of management’s present expectations and convictions.

Yet, like stars that guide a ship through uncharted waters, these statements are not immune to the twists and turns of uncertainty. We acknowledge the risks, the shadows that tread alongside our ambitions, including the possibility that our journey toward non-GAAP profitability in 2023 may encounter its challenges. Delve deeper, and you’ll uncover the layers of our story—details etched in our Annual Report on Form 10-K for the year ending December 31, 2022.

As time unfolds, the tapestry of reality may diverge from the sketches we paint here, a reminder to tread lightly upon the promises made. We stand humbly at this juncture, mindful of the unscripted chapters ahead. The words on these pages are not shackles, but an invitation—a vibrant journey fueled by hope and guided by caution.”

Leave a Comment